Post intra-alveolar extraction pain control with Bupivacaine and Lidocaine

Not Applicable

• Conditions: Anaesthesia

• Registration Number: PACTR201812526365048
• Lead Sponsor: ADELUSI EMMANUEL ADETO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

All dental patients of age 18 years and above who required intra-alveolar tooth extraction and who consented to participate in the study.

Exclusion Criteria

Patients who required surgical removal of the tooth/teeth
Patients with history of allergy to bupivacaine or lidocaine.
Patients with cognitive problems e.g. mental retardation, cerebral palsy.
Patients with underlying systemic diseases such as uncontrolled diabetic mellitus, hypertension.
Regular smoker (2 or more sticks per day) and regular/heavy alcohol intake (more than three drinks (1065ml) of beer per day or more than seven drinks (4970ml) of beer per week, more than three drinks (444ml) of wine per day or more than seven drinks (1036ml) of wine per week, more than three drinks (132ml) of distilled spirit per day or more than seven drinks (308ml) of distilled spirit per week).139, 140, 141
Patients who were on antibiotics, oral contraceptive, or steroid therapy
Patients who could not read and write.
Patients with complicated tooth extraction (more than 30minutes)
Patients with tooth mobility greater than grade I
Patients with dentoalveolar abscess, orofacial cellulitis or abscess
Pregnant patients (bupivacaine crosses the placenta barrier to the baby)
Patients with known allergy to adrenaline
Patients who declined participation in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified